Cicero Diagnostics, based in Huntington Beach, CA, is a trusted provider of innovative testing solutions for fertility centers worldwide. Their flagship product, ReceptivaDx, offers a groundbreaking approach to detecting defects in the uterine lining that contribute to unexplained infertility, implantation failure, and recurrent pregnancy loss. By analyzing endometrial tissue obtained through a biopsy, ReceptivaDx can identify inflammation associated with asymptomatic endometriosis without the need for invasive surgery. With a high sensitivity and specificity, the test provides a reliable and less invasive method for detecting endometriosis, offering new hope and treatment pathways for challenging fertility cases.
Supported by extensive published clinical data and ongoing research collaborations with prestigious academic institutions, Cicero Diagnostics is at the forefront of advancing knowledge and understanding in the field of reproductive medicine. Their Shared Experience Program, established in 2019, fosters collaboration with high-volume referring clients across the United States, enabling the collection of treatment and outcome data based on patients testing positive for ReceptivaDx markers. With over 10,000 patients tested and partnerships with more than 300 fertility centers worldwide, Cicero Diagnostics continues to make significant contributions to the diagnosis and treatment of endometriosis-related infertility.
Generated from the website
